Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI) reported its Q4 and fiscal year 2021 results, revealing significant increases in operating expenses totaling $27.8 million in Q4, leading to a net loss of $29.4 million. For the fiscal year, total net loss reached $95.0 million, up from $36.6 million in 2020. The company ended the year with $471.3 million in cash and equivalents, positioning it well for upcoming product launches in 2022. They formed a new Scientific Advisory Board, expanded staff from 72 to 153, and entered strategic partnerships to enhance research applications.
Quantum-Si (NASDAQ: QSI) announced its participation in the 42nd Annual Cowen Health Care Conference, scheduled for March 8, 2022, at 2:10 pm ET. The presentation will be held virtually, and interested parties can access a live webcast on the Quantum-Si investor website. A replay will be available post-event. Quantum-Si is pioneering the field of proteomics with its innovative semiconductor chip that enables single molecule protein sequencing, advancing drug discovery and diagnostics.
Quantum-Si (NASDAQ: QSI) announced the appointment of Dr. Jonathan Rothberg as Interim CEO, effective February 8, 2022. Dr. Rothberg, founder and Executive Chairman, will lead the company during the transition as it searches for a permanent CEO. Quantum-Si focuses on revolutionary single molecule protein sequencing, similar to the impact of DNA sequencing in oncology. The company aims to commercialize its groundbreaking technology in 2022, emphasizing its importance in understanding immune responses to COVID-19. Financial results for Q4 and full year 2021 will be reported on February 28, 2022.
Quantum-Si Incorporated (Nasdaq: QSI) will report fourth quarter and full year 2021 financial results after market close on February 28, 2022. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. Quantum-Si focuses on commercializing a unique single molecule protein sequencing platform, aiming to revolutionize proteomics and advance drug discovery. Founded in 2013 by Dr. Jonathan Rothberg, the company utilizes an innovative semiconductor chip designed for next-generation protein sequencing.
Quantum-Si Incorporated (Nasdaq: QSI) announced key updates ahead of the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. They established list prices for their protein sequencing platform: $70,000 for the PlatinumTM Analyzer and $20,000 for the CarbonTM sampler, with pre-orders starting in H1 2022. The company also published a technical manuscript on bioRxiv, detailing advancements in single-molecule protein sequencing. CEO John Stark emphasized the company's growth momentum and plans for commercialization in 2022.
Quantum-Si (QSI) announced its relocation to new headquarters at the Winchester Works site in Guilford, Connecticut, in the first half of 2022. The 65,000 square-foot facility will enhance R&D and office space, furthering QSI's mission to advance protein sequencing technology. This strategic move follows the opening of a San Diego facility in late 2021, emphasizing QSI's commitment to growth in vital life sciences hubs. The CEO highlighted the importance of these campuses for talent recruitment ahead of the platform's commercial launch.
Quantum-Si, a life sciences tools company specializing in protein sequencing, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The company's management will present virtually on January 12, 2022, at 4:30 PM ET. A live webcast will be accessible through Quantum-Si's investor website, with a replay available afterward. Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to innovate proteomics using a unique semiconductor chip for next-generation protein sequencing and advancements in drug discovery.
Detect, Inc. has launched its FDA-authorized PCR-quality at-home Covid-19 test for consumer purchase at $49. This rapid test is at least 50 times more sensitive than leading antigen tests, delivering results in one hour, with an accuracy agreement of 97.3% against highly sensitive PCR tests. The company appointed consumer tech veteran Hugo Barra as CEO to enhance its growth. Detect also offers a telehealth service for certified results at $20. They have raised $110M in funding and received an $8.1M contract from the NIH to scale manufacturing.
Quantum-Si (Nasdaq: QSI) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of its annual reconstitution, effective December 20, 2021. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities based on specific eligibility criteria such as market capitalization and trading volume. Quantum-Si specializes in protein sequencing technology, aiming to enhance drug discovery and diagnostics through its innovative semiconductor chip designed for single molecule sequencing.
Quantum-Si (NASDAQ: QSI) announced its Q3 2021 financial results, reporting a net loss of $18.1 million, up from $8.6 million in Q3 2020. Operating expenses surged to $25.2 million, largely due to increased hiring and efforts in product development. The Early Access program expanded to ten sites, enhancing collaboration with academia and industry. The company also aims to bolster its chip production capabilities by acquiring Majelac Technologies. As of September 30, 2021, Quantum-Si has $500.2 million in cash and equivalents, positioning it well for future growth.